id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-N-0516-0064,FDA,FDA-2005-N-0516,Reference,Supporting & Related Material,REF-Reference (internal unless indicated),2005-11-04T05:00:00Z,2005,11,,,2008-04-11T23:59:20Z,,0,0,090000648047fa0c
FDA-2005-N-0516-0149,FDA,FDA-2005-N-0516,"FDA/CDER Response to W. David Hager, M.D.[Department of Obstetrics and Gynecology, University of Kentucky] - Letter",Other,LET-Letter,2005-10-05T04:00:00Z,2005,10,,,2008-12-04T23:13:37Z,,0,0,090000648047b3c3
FDA-2005-N-0516-0001,FDA,FDA-2005-N-0516,Drug Approvals:Circumstances Under Which an Active Ingredients may be Simultaneously Marketed in Both a Prescription Drug Product and an Over-the-Counter Drug Product,Proposed Rule,NAP-Advanced Notice of Proposed Rulemaking,2005-08-26T04:00:00Z,2005,8,2005-08-26T04:00:00Z,2005-11-02T04:59:59Z,2008-12-04T23:18:11Z,,0,0,090000648047abb3